Taking a Healthy Interest in You
An agency of the Ministry of Health
ISO 9001:2008 Certified
NHF Adjusts Subsidy on 432 Prescription Items & Diabetic Supplies and Adds New Drugs for Five Conditions
National Health Fund (NHF) cardholders are to benefit from increases in the subsidies of 432 prescription items and diabetic supplies. This adjustment to the subsidies will result in a $100M increase in expenditure for the NHF Card programme. The increases became effective on April 3, 2017.
The NHF has also added new drugs for the treatment of Diabetes Mellitus, Hypertension, Ischaemic Heart Disease, Prostate Cancer and Vascular Disease. New, for the treatment of Diabetes Mellitus, is Trajenta tablets with the active ingredient Linagliptin, and NHF offers a subsidy of $103.83 per 5mg tablet.
Epnone tablets with the active ingredient Eplerenone with a subsidy of $97.50 per 25mg tablet and $195.00 per 50mg tablet has been added for the treatment of Hypertension. Ran-CV ER tablets with active ingredient Ranolazine ER with a subsidy of $91.00 per 500mg tablet has been added for Ischaemic Heart Disease.
In addition, Firmagon Injections with active ingredient Degarelix Acetate for Prostate Cancer have also been added with a subsidy of $17,698.40 per 80mg injection and $26,547.60 per 120mg injection. Doxium capsules with active ingredient Calcium Dobesilate for the treatment of Vascular Disease is now subsidized. The NHF offers a subsidy of $81.84 per capsule. These changes became effective April 4, 2017.
A complete drug list and subsidies paid by the National Health Fund are available from NHF participating Pharmacies, the NHF website or by calling NHF (1-888-NHF-CARE).
Contact: Shermaine Robotham, Tel. 832-8675/ 906-1106